Objective:

To evaluate the safety and efficacy of the novel perflutren-based ultrasound-enhancing agent MVT-100 compared to Definity in healthy volunteers.

Approach:

• Study Design: A prospective interventional phase 1/2 study involving healthy volunteers who underwent echocardiography and received ascending dilute bolus doses of MVT-100 or Definity.
• Monitoring: Participants were monitored for vital signs, ECGs, and laboratory tests before and after contrast administration.
• Evaluation: Three expert echocardiographers evaluated images for left ventricular opacification and acoustic shadowing, blinded to the administered agent.

Key Findings:

• No serious adverse events reported for either MVT-100 or Definity.
• No clinically significant changes in vital signs, ECG, or laboratory parameters post-administration.
• MVT-100 produced higher left ventricular opacification scores than Definity across all dose levels.
• Overall shadowing rates were approximately 3% with MVT-100 compared to 8% with Definity.
• Statistically significant reductions in acoustic shadowing observed across most left ventricular segments.

Interpretation:

Limitations:

• Study details and formal disclosure information were not provided in the abstract materials.

Conclusion:

Sources:

• Journal of the American Society of Echocardiography